Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06696118

Electromagnetic Transduction Therapy on Osteoarthritis in the Foot and Ankle

The purpose of this study is to determine if Electromagnetic Transduction Therapy (EMTT) is a viable treatment option in patients with osteoarthritis of the foot and/or ankle.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Osteoarthritis Ankle Osteoarthritis Foot

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women with osteoarthritis of the foot and/or ankle confirmed via radiographs.

Exclusion criteria

  • Pacemaker, active cancer, shrapnel, metal in eye, implantable devices that are not compatible with MRIs, concurrent foot or ankle condition or injury, prior foot or ankle surgery for osteoarthritis, steroid, platelet rich plasma, or hyaluronic acid injection within 2 months of the treatment.

Treatment and study plan

Electromagnetic transduction therapy (EMTT)

Device

Subjects will be treated with Electromagnetic Transduction Therapy (EMTT) using the Curamedix MAGNETOLITH device. Treatments will be administered twice per week, for four weeks. Each treatment will have the following settings: level 8, 8Hz, and 10,000 pulses andwill take about 15 to 20 minutes. Treatments will be spaced 2-3 days apart.

Primary outcomes

  1. Visual Analog Scale (VAS) for Pain

    Time frame: Baseline, 3 weeks, 3 months, 6 months

    The VAS is a 11-item questionnaire assessing pain. Using a scale of 0 = no pain to 10 = worst pain. Total scores range from 0 - 110, lower scores indicating lower pain and higher scores indicating greater pain.

  2. Foot and Ankle Ability Measure (FAAM)

    Time frame: Baseline, 3 weeks, 3 months, 6 months

    The Foot and Ankle Ability Measure (FAAM) ADL is a 21-item self-report questionnaire measuring Activities of Daily Living. Each item is scored on a 5-point Likert scale (4 to 0) from 'no difficulty at all' to 'unable to do'. Item score totals, which range from 0 to 84 are reported in percentage scores. Higher scores represent higher levels of function, with 100% representing no dysfunction.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Electromagnetic Transduction Therapy (EMTT) on Mid-foot Osteoarthritis: A Pilot Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Nov 20, 2024
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.